BioWorld

April 28, 2004

Early Erbitux Revenue Propels ImClone Into Profitable Waters

Modified Bacteria Could Stimulate Immune Response Against Cancer

Wyeth Exits Deal For FluMist, Gives MedImmune Full Rights

Other News To Note

AGT Biosciences Picking Up ChemGenex In A$14M Merger

ChemGenex Therapeutics Inc. and AGT Biosciences Ltd. are merging to form a genomics-driven pharmaceutical firm with leading-edge technology and two cancer drugs in clinical trials, officials from both companies said. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...